Trump Orders FDA to Fast-Track Psychedelic Drug Reviews

Is fast-tracking ibogaine for veterans a life-saving breakthrough or a reckless gamble with their lives?

Published 18 hours ago·Updated 11 hours ago

Trump Orders FDA to Fast-Track Psychedelic Drug Reviews

story

Above: Donald Trump in the Oval Office on April 18, 2026. Image credit: Tasos Katopodis/Getty Images

The Spin

Pro-establishment narrative

Fast-tracking psychedelics like ibogaine is reckless when the drug is linked to fatal heart problems and has caused more than 30 deaths in medical literature. The Stanford study backing ibogaine enrolled just 30 veterans with no placebo group — that's not rigorous science, that's a photo op. Cutting bureaucratic corners on a Schedule I drug with known cardiovascular toxicity puts vulnerable veterans at serious risk.

The Washington Post US News & World Report

Establishment-critical narrative

Veterans are dying while outdated stigmas and bureaucratic red tape block treatments that have already changed lives. Conventional options like opioids have failed, and ibogaine has delivered real, documented results for combat-related PTSD where nothing else worked. This executive order finally clears away unnecessary bureaucratic hurdles and puts results and veteran well-being ahead of institutional inertia.

Don Keith on X

Congressman Morgan Luttrell on X

Derrick Evans on X